Skip to main content
. Author manuscript; available in PMC: 2016 Nov 2.
Published in final edited form as: Cancer Lett. 2008 Jun 18;270(1):132–143. doi: 10.1016/j.canlet.2008.04.053

Fig. 4.

Fig. 4

Sensitivity of prostate cancer cells to cisplatin and etoposide. (A) 22Rv1, LNCaP and PC3 cells were treated with cisplatin (0–100 μM) or (B) etoposide (0–300 μM) for 24 h. Cell death was measured using LDH release assay. n = 4 per group, *p <0.05, **p <0.01, ***p < 0.001 compared to zero point for the same cell line.